Biotechnology News & Press Release Distribution

Biotechnology

APAC
Global

Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel

PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership withAlbireo ...

2022-08-16 19:30 2312

Profitable growth continues: Exyte with remarkable 6M/2022 results and uplifted year-end outlook

- Order intake rose by almost 50 percent year-on-year, marking a new 6M-high with €4.7 billion - Sales volume increased by almost 50 percent to €3.4 billion - Adjusted EBIT increased by approximately two thirds to €202 million; adjusted EBITDA rose to €222 million, plus over 60 percent - Global...

2022-08-16 16:24 2228

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

* World First Regenerative Aesthetic Exosome Summit (RAES 2022) * Participation of Global Exosome and Regenerative Aesthetic Authorities * Plan to Grow into a Global Platform for Exosome and Regenerative Aesthetic Industry in the Future SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCo...

2022-08-16 15:00 5657

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi ...

2022-08-16 14:48 2694

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held inVienna, Austria, during the official s...

2022-08-16 13:35 1532

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitorthat targets the DNA damage response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology...

2022-08-16 08:30 2710

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

* BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 15, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing ...

2022-08-16 08:17 1688

Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories

Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-...

2022-08-16 07:15 2677

ROKIT Healthcare to Enable Innovation in Treatment of Diabetes Foot and Osteoarthritis Combining AI and 3D Bioprinting on Google Cloud

SEOUL, South Korea, Aug. 15, 2022 /PRNewswire/ -- ROKIT Healthcare, a company specializing in bio-healthcare, today announced it will provide a hyper-personalized medical platform that uses 3D bioprinting and AI technology built on Google Cloud, to innovate the treatment of osteoarthritis and dia...

2022-08-15 07:00 4571

ROKIT Healthcare to Enable Innovation in Treatment of Diabetes Foot and Osteoarthritis Combining AI and 3D Bioprinting on Google Cloud

Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

* Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and co...

2022-08-12 21:39 10085

JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.

SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcomin...

2022-08-12 10:13 1631

JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.

WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU ...

2022-08-12 09:09 1768

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

Taiwan FDA accepts New Drug Application for Xerava for treatment of cIAI Everest enters into strategic partnership with TTY Biopharm for the commercialization of Xerava inTaiwan SHANGHAI, Aug. 11, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK...

2022-08-11 08:00 2510

Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID

SEOUL, South Korea, Aug. 10, 2022 /PRNewswire/ -- Panacell Biotech Co., Ltd. said that NK cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness.

2022-08-10 22:00 2555

Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID

WeTrade Group Entered Into A Strategic Partnership With Jiqing, Acquiring Monkeypox Test Kits Exclusive Sales Channel

BEIJING, Aug. 10, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, officially singed the strategic partnership agre...

2022-08-10 20:36 2091

WeTrade Group Entered Into A Strategic Partnership With Jiqing, Acquiring Monkeypox Test Kits Exclusive Sales Channel

Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently completed the subject enrollment and first dose vaccination in respect of immun...

2022-08-10 16:06 2385

Starpharma signs new DEP® agreement with MSD

MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...

2022-08-10 15:29 1653

Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022

* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients * A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 9, 2022 /PRNewswire/...

2022-08-10 11:43 1575

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). ...

2022-08-10 10:00 2526

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform

* CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes * Customized gene editing technology for unique modified-bacteriophages * To validate efficacy of SARS-CoV-2 mimotopes loaded PHAGERUS® platform BOSTON and SEOUL, South Korea, Aug. 9, 2022 /PRNewswire/ -- iNtRON ...

2022-08-10 09:00 1423

1 ... 117 118 119120121 122 123 ... 279